Science And Technology Company Launched A Quarterly Dismantling: Pharmaceutical Stocks Differentiation, Technology Leader, Strong Pressure

In April 16th, the first scientific innovation plate was released in the first place, and BOLN 688058.SH first disclosed the first quarter results in 2020.

The main software development of BOLN Germany achieved a profit of 8 million 922 thousand yuan in the first quarter, a decrease of 4.86% compared with the same period last year, and net profit of 1 million 333 thousand yuan, a 66.87% decrease compared with the same period last year.

In this regard, BOLN Germany explained that revenue reduction is mainly affected by the epidemic this quarter, the main client's contract signing and revenue recognition have been affected to varying degrees, the new industry customer development process is limited and so on.

"Due to the time effect of isolation, resumption and resumption of production can reach the normal state", BOLN Germany has made every effort to take measures to reduce losses and increase profits, but "it is expected that the next reporting period may be a loss or a significant change compared with the same period last year."

Followed by 688358.SH. In April 17th, the main medical ultrasound disclosure of ultrasound medical imaging equipment achieved a revenue of 67 million 58 thousand yuan in the first quarter, an increase of 31.45% over the same period, and a net profit of 17 million 387 thousand yuan, an increase of 210.9% over the same period.

Wind data show that as of April 22nd, 9 of the 98 listed companies of the science and technology innovation board launched the first quarterly bulletin in 2020. Besides Bao Lan and Xiangsheng medical care, there were also 688166.SH, 688085.SH, 688198.SH, 688278.SH, 688019.SH, and 688030.SH. Zhuo Yi information (688258.SH).

This week, 16 companies will announce a quarterly report, while the remaining 72 of 688016.SH will be disclosed in the last week of April. Under the influence of the epidemic, the performance of GEM companies has plummeted. How is the performance of the company?

Differentiation of pharmaceutical stocks

Of the 9 companies that have disclosed quarterly reports, 5 belong to the pharmaceutical and biological sectors.

However, even if it belongs to the pharmaceutical sector, the performance of many companies is obviously divided: Xiangsheng medical, Bo Rui medicine, and Po bio are not afraid of the epidemic. They have delivered a good "report card", while the less than a month of the three friends listed, the net profit of the first quarter has declined.

In the first quarter of the year, the two new institutional investors were outstanding. The sixth largest shareholders were "Shanghai (Cci Capital Ltd) - No. 3 private equity investment fund" and the eighth largest shareholder "industrial and Commercial Bank - financing and health industry, flexible allocation of hybrid securities investment fund", with 1 million 262 thousand and 500 shares and 793 thousand and 900 shares respectively.

At the same time, compared to the beginning of this year, the nine largest shareholder of Xiangsheng medical group, the "Construction Bank the Great Wall consumer value added hybrid investment fund" and the tenth largest shareholder, "Bank of Communications the Great Wall long rich core growth Mixed Securities Investment Fund (LOF)", were added in the first quarter, opening 463 thousand shares and 253 thousand and 900 shares respectively, holding 663 thousand shares and 601 thousand and 800 shares respectively.

In April 20th, pharmaceutical company Bo Rui medicine announced a quarterly report in 2020, operating income of 130 million yuan, an increase of 45.16% over the same period, and net profit of 34 million 26 thousand yuan, an increase of 111.07% over the same period last year.

In November 8, 2019, Bo Rui medicine landed in the science and technology board, developing and producing high-end generic drugs and original new drugs. Its revenue comes from sales of products such as antifungal, antiviral and immunosuppressive products, as well as the transfer of technology or services, and the income sharing of products.

"In the first quarter of 2020, the performance of Bo Rui pharmaceutical increased substantially, mainly due to the continuation of the good sales trend of major products in 2019, and little to do with the outbreak of the new coronavirus." Wang Zhengye, director of medicine, said in an interview with the media that sales of all products in the company in the first quarter of 2020 were not small.

A quarterly show shows that Bo Rui medicine is favored by social security, pensions and many public offering and brokerage institutions. The 16061 combination of pensions, Yinhua Fund - Guo Xin Investment Co., Ltd. - Yinhua Fund - Guo Xin 1 single asset management plan, Harvest Fund - China Merchants Bank - Huarun Shenzhen Investment Trust - Huarun trust Heng Sheng fund trust scheme holds 2 million 863 thousand and 800 shares and 514 thousand shares respectively And 443 thousand strands.

Coincidentally, benefiting from the growth of sales of main products, the net profit of special bio products in the first quarter was 22 million 359 thousand yuan, up 40 times compared with the same period last year.

In April 22nd, the reporter called the special bio securities affairs department, and its staff said, "the first quarter growth of the company has benefited from the increase in the sales volume of the main products, and whether the epidemic will affect the two quarter remains to be seen."

It focuses on the development, production and marketing of recombinant protein and its long-term modifying drugs, and focuses on the field of chronic hepatitis B treatment. In 2019, biotech products were listed, including the 1 class of new products, the pegylated interferon. Alpha -2b injection (trade name "pie"), Recombinant Human Granulocyte/Macrophage Colony-stimulating Factor for Injection (trade name "Tel Li"), Recombinant Human Granulocyte Colony-stimulating Factor Injection (trade name "Tel Jin") and Recombinant Human Interleukin-11 for Injection (trade name "Tel Kang").

Guang Fa star fund manager Liu Gesong once mentioned that "the uncertainty of the epidemic situation and the deep adjustment of the crude oil price make the risk assets in the global scope obvious adjustment. In the first quarter of 2020, the A share market was affected by the new crown pneumonia epidemic and overseas market shocks, and the fluctuation was relatively large. The fund was mainly equipped with technology growth, medical and biological, new energy industries and some high-quality consumer companies, and the allocation of medical services industry increased.

In contrast, Sanyou medical treatment is not so lucky.

In April 9, 2020, the Sanyou medical company, which landed on the science and technology board, was listed for less than a month.

In the first quarter, Sanyou medical revenue achieved 49 million 663 thousand and 700 yuan, down 30.59% compared with the same period last year, net profit 11 million 910 thousand and 800 yuan, down 39.18% compared with the same period last year.

In the previous performance notice, Sanyou medical care is also a precautionary measure. "Affected by the outbreak of the new crown pneumonia outbreak in 2020 and the early start of the Spring Festival holiday, the operation volume of Department of orthopedics in the terminal hospital has been greatly reduced since late January 2020, and the operating income has declined correspondingly. The company has the risk of a substantial decrease in operating income and net profit in the first quarter of 2020 compared with the same period last year."

Benevolent medical care, which focuses on animal derived medical devices, has also been badly affected by the epidemic.

In the first quarter of this year, the revenue of Bai Ren medical was 23 million 662 thousand yuan, down 24.68% from the same period last year, and net profit was 8 million 963 thousand yuan, down 31.13% compared with the same period last year.

However, in the past 2019, Bai Ren's medical performance was stable, with a revenue of 146 million yuan, an increase of 31.98% over the same period, and a net profit of 63 million 80 thousand yuan, an increase of 88.88% over the same period last year.

Science and technology leader is strong

Then, what are the achievements of the listed companies in the non pharmaceutical and biological industries?

The main technology of semiconductor materials, Anji technology, achieved a revenue of 96 million 338 thousand yuan in the first quarter, an increase of 64.06% over the same period, and a net profit of 23 million 556 thousand yuan, an increase of more than 4 times over the same period last year.

In terms of market performance, Anji technology rose 20% in April 22nd.

Anji technology says revenue growth is mainly due to increased customer usage. The official website shows that the products of Anji technology include different series of chemical mechanical polishing fluid and photoresist remover, mainly used in integrated circuit chip manufacturing and advanced packaging field.

In addition, Zhuo Yi, which provides cloud computing services, is "eye-catching". It achieved a profit of 28 million 656 thousand yuan in 1-3 this year, an increase of 26.66% over the same period last year, and net profit of 9 million 215 thousand yuan, up 45.36% over the same period last year.

Zhuo Yi's cloud computing device core firmware (BIOS, BMC) technology and cloud platform technology with independent intellectual property rights provide BIOS, BMC firmware development and cloud services for cloud computing equipment manufacturers, government and enterprise customers. In the long run, the value of Zhuo information depends on whether cloud computing equipment firmware and cloud computing services can be launched outside Yixing, Jiangsu.

From the perspective of the theme fund, the information technology sector is also attracting much attention.

For example, huitianfu technology innovation and flexible configuration of mixed position in the first quarter of the level of 84.4%, compared with 2019 at the end of 93.18% reduced nearly 10 percentage points, but specifically, it also added pharmaceutical stocks and IT shares. Among them, in terms of medicine, it focuses on investing in research and development of innovative drugs, in vitro diagnostics, cardiovascular devices and other industries, while IT focuses on financial IT, B2B business, SaaS services, online video and other industries.

However, in April 22nd, the science and Technology Publishing Group published a 57 million 867 thousand and 100 yuan net income in the first quarter of 2020, a decrease of 21.34% compared with the same period last year. Net profit was 69 million 894 thousand and 200 yuan for the loss, and net profit for the same period last year was 51 million 971 thousand and 700 yuan.

Regarding this, in April 22nd, the related personage of the mountain net Department told the economic report in twenty-first Century, "the quarterly performance of the company has declined to a certain extent, which is mainly affected by the new crown epidemic situation. It has been deferred to some extent in terms of customer demand, project development, logistics supply and so on. In addition, based on the characteristics of the network security industry, the company's order distribution is seasonal, and the company's products and services are in line with each other. The sales revenue is concentrated in the second half of the year, especially in the fourth quarter, while the expenditure on R & D investment, personnel wages and other expenses is relatively uniform, resulting in the uneven distribution of net profit in the whole year.

Can the science and technology board lead the first quarter market?

Among the companies that have not yet disclosed a quarterly bulletin board, 6 have made performance forecasts, and 3 have increased in advance. They will announce 688096.SH, 688189.SH and Jiahua Technology (688051.SH) on a quarterly basis on April 28th, 29 and 30 respectively, and 2 expect the first loss in the first quarter to be the Shanghai silicon industry (688126.SH) and the Chengdu leader (688222.SH).

Nan Xin Pharmaceutical expects net profit of about 25 million 880 thousand yuan -3076 million yuan in this year, an increase of 25.78%-49.51%. It said that since the "new crown pneumonia epidemic", the company's production and operation activities are normal. In order to ensure the full supply of antiviral drugs throughout the country, the company's production and sales volume increased.

In addition, the first quarter net profit growth of 489.56%-672.6% to about 22 million 612 thousand and 700 yuan -2963.32 million yuan Jiahua technology is expected to be summed up as "mainly the company's wisdom and environmental protection, smart city business revenue growth is relatively fast."

In contrast, Shanghai silicon industry expects net profit in the first quarter to be about 65 million 200 thousand yuan to a loss of 47 million 200 thousand yuan, a decrease of 517.92%-677.29%, which is an uproar.

In this regard, Shanghai silicon industry explained that "the company's 300mm semiconductor wafer business was affected by the decline of the semiconductor industry boom in the first quarter of 2020, and the average selling price of the product still declined compared with the same period last year. At the same time, the 300mm semiconductor silicon wafer reverse operation strategy in 2019 continued to invest in machinery and equipment, resulting in the depreciation and maintenance of machinery and equipment in the first quarter of the operating cost. The fixed costs of protection and indirect labor and energy increased compared with the same period last year. Therefore, this part of the business is expected to increase significantly in losses compared with the same period last year.

The poor performance of the Chengdu leader is expected to net profit of about 10 million yuan to 5 million yuan in the first quarter, a decrease of 111.26%-122.51%.

688228.SH is more uncertain. "The acceptance of the first quarter of 2020 is affected by the current pneumonia epidemic, and the income is expected to be uncertain. And due to seasonal factors, the scale of income in the first quarter is relatively small, and the fluctuation of the profit level is expected to be larger."

Can the science and technology board lead the first quarter market?

A brokerage analyst in Shanghai believes that "three scientific and technological innovation sectors, including medicine, IT and high-end manufacturing, deserve our attention. Within the plate, we are optimistic about the relatively clear competitive sub sectors and the leading companies with competitive advantages."

?